ArticleLife (Basel, Switzerland)2022
The Occurrence of Nephrolithiasis in Gout Patients: A Longitudinal Follow-Up Study Using a National Health Screening Cohort.
Article in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Article
- Characteristics and Management of Uncontrolled Gout Prior to Pegloticase Therapy: A 2-year Claims Analysis.Rheumatology and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
The association of gout with nephrolithiasis has been suggested. The current study investigated the risk of nephrolithiasis in patients with gout. The relationship of nephrolithiasis with gout was assessed according to patient characteristics. Individuals in the Korean National Health Insurance Service−Health Screening Cohort were examined. The 17,043 participants with gout were paired with 68,172 comparison participants. The diagnosis of nephrolithiasis was examined in both the gout and control groups. The possible risk of nephrolithiasis in the gout group was analyzed using a stratified Cox proportional hazards model. Subcategory analyses were conducted according to demographic features and comorbidities. The rate of nephrolithiasis was 3.3% (569/17,043) in the gout group and 2.6% (1786/68,172) in the control group. The adjusted hazard ratio (aHR) of gout for nephrolithiasis was 1.23 (95% confidence intervals [95% CI] = 1.12−1.36) in the overall study population. The < 60 years and male groups showed an increased risk of nephrolithiasis related to gout (aHR = 1.26 [1.13−1.42] for the < 60 years group; aHR = 1.27 [1.15−1.41] for the male group). Regarding comorbidities, all subgroups except for the underweight, overweight, total cholesterol ≥ 240 mg/dL, fasting blood glucose ≥ 100 mg/dL, and CCI score 1 and ≥ 2 groups showed a higher risk of nephrolithiasis in gout patients. The gout patients presented an increased occurrence of nephrolithiasis. The middle-aged, male, and healthy populations showed consistently higher HRs of nephrolithiasis related to gout.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.